First published in the Government *Gazette*, Electronic Edition, on 30 April 2020 at 5 pm.

No. S 349

MISUSE OF DRUGS ACT
(CHAPTER 185)

MISUSE OF DRUGS ACT
(AMENDMENT OF FIRST, THIRD AND FIFTH SCHEDULES) ORDER 2020

In exercise of the powers conferred by sections 58A and 59 of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Order:

Citation and commencement

1. This Order is the Misuse of Drugs Act (Amendment of First, Third and Fifth Schedules) Order 2020 and comes into operation on 1 May 2020.

Amendment of Part I of First Schedule

2. Part I of the First Schedule to the Misuse of Drugs Act is amended —

(*a*) by deleting item (19) of paragraph 1 and substituting the following item:

> "(19) 1-(4-Bromo-2,5-dimethoxyphenyl)propan-2-amine (also known as 4-Bromo-2,5-dimethoxy-α-methylphenethylamine, 4-Bromo-2,5-dimethoxyamphetamine, Brolamfetamine or DOB) and its bromo and dimethoxy positional isomers in the phenyl ring";

(*b*) by deleting item (44) of paragraph 1 and substituting the following item:

> "(44) 1-(2,5-Dimethoxy-4-methylphenyl)propan-2-amine (also known as 2,5-Dimethoxy-4, α-dimethylphenethylamine, 2-Amino-1-(2,5-dimethoxy-4-methyl)phenylpropane or DOM)

and its methyl and dimethoxy positional isomers in the phenyl ring";

(*c*) by inserting, immediately after item (8) of paragraph 7, the following item:

"(8AAA) Crotonylfentanyl";

(*d*) by inserting, immediately after item (13) of paragraph 7, the following item:

"(14) Valerylfentanyl";

(*e*) by deleting item (12A) of paragraph 16 and substituting the following item:

"(12A) 2-(Ethylamino)-1-phenylhexan-1-one (also known as N-Ethylhexedrone or Ethyl-hexedrone)";

(*f*) by inserting, immediately after item (24) of paragraph 16, the following item:

"(24A) 1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one (also known as Alpha-Pyrrolidinohexiophenone or Alpha-PHP or α-PHP)";

(*g*) by inserting, immediately after item (2) of paragraph 18, the following item:

"(2AAA) 6-Allyl-6-nor-lysergic acid diethylamide (also known as N-Allyl-nor-LSD or AL-LAD) and its acyclic secondary and tertiary amide structural isomers";

(*h*) by inserting, immediately after item (2A) of paragraph 18, the following item:

"(2AAB) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide (also known as 2-[(1-Butyl-1H-indazol-3-yl)formamido]-3,3-dimethylbutanamide or ADB-BUTINACA) and its N-(1-amino-1-oxohexan-2-yl) isomers";

(*i*) by inserting, immediately after item (2CA) of paragraph 18, the following item:

"(2CB) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-hydroxybutyl)-1H-indazole-3-carboxamide and its N-(1-amino-1-oxohexan-2-yl) isomers and their

respective hydroxy positional isomers in the butyl group";

(*j*) by deleting item (2G) of paragraph 18 and substituting the following item:

"(2G) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as N-[1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl) methyl]-1H-indazole-3-carboxamide or AB-FUBINACA) and its N-(1-amino-1-oxopentan-2-yl) and N-(1-amino-2-methyl-1-oxobutan-2-yl) isomers and their respective fluoro positional isomers in the phenyl ring";

(*k*) by inserting, immediately after item (6G) of paragraph 18, the following items:

"(6H) 1-Butanoyl-N,N-diethyllysergamide (also known as 1-Butanoyl-LSD or 1B-LSD) and its acyclic secondary and tertiary amide structural isomers

(6I) 2-(1-Butyl-1H-indazole-3-carboxamido)-3,3-dimethylbutanoic acid and its hexanoic acid isomers";

(*l*) by inserting, immediately after item (8) of paragraph 18, the following item:

"(8AAA) 1-(4-Chloro-2,5-dimethoxyphenyl)propan-2-amine (also known as 4-Chloro-2,5-dimethoxy-α-methylphenethylamine, 4-Chloro-2,5-dimethoxyamphetamine, DOC, 3C-C, 4-Cl-2,5-DMA or 4-Chloro-2,5-DMA) and its chloro and dimethoxy positional isomers in the phenyl ring";

(*m*) by inserting, immediately after item (14) of paragraph 18, the following item:

"(14A) 2-[1-(4,5-Dihydroxypentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid and its hexanoic acid isomers and their respective dihydroxy positional isomers in the pentyl group";

(*n*) by inserting, immediately after item (19AAB) of paragraph 18, the following item:

"(19AAC) 6-Ethyl-6-nor-lysergic acid diethylamide (also known as ETH-LAD) and its acyclic secondary and tertiary amide structural isomers";

(*o*) by inserting, immediately after item (19ABE) of paragraph 18, the following item:

"(19ABF) 2-Fluorodeschloroketamine (also known as 2-Fluoroketamine or 2-FDCK) and its fluoro positional isomers in the phenyl ring";

(*p*) by inserting, immediately after item (20AA) of paragraph 18, the following item:

"(20AB) 5-(5-Fluoropentyl)-2-(2-phenylpropan-2-yl)-pyrido [4,3-b]indol-1-one (also known as 2-Cumyl-5-(5-fluoropentyl)-gamma-carbolin-1-one or 5-Fluoro-cumyl-PEGACLONE) and its phenylpropyl isomers and their respective fluoro positional isomers in the pentyl group";

(*q*) by inserting, immediately after item (27DA) of paragraph 18, the following item:

"(27DB) Lysergic acid 2,4-dimethylazetidide (also known as LSZ)";

(*r*) by deleting item (28GA) of paragraph 18 and substituting the following item:

"(28GA) Methyl 2-[1-(4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl 2-{[1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate, 4F-MDMB-BINACA, 4F-MDMB-BUTINACA or 4-Fluoro-MDMB-BINACA) and its hexanoate isomers and their respective fluoro positional isomers in the butyl group";

(*s*) by deleting items (28I) and (28J) of paragraph 18 and substituting the following items:

"(28I) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as Methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3-methylbutanoate, 5F-AMP, 5-Fluoro-AMP, 5F-MMB-PINACA, 5F-AMB-PINACA, 5-Fluoro-AMB or

5-Fluoro-MMB-PINACA) and its pentanoate isomers and their respective fluoro positional isomers in the pentyl group

(28J) Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl 2-{[1-(5-fluoropentyl)-1H-indole-3-carbonyl] amino}-3,3-dimethylbutanoate, 5F-MDMB-PICA, 5F-MDMB-2201, 5-Fluoro-MDMB-2201 or 5-Fluoro-MDMB-PICA) and its hexanoate isomers and their respective fluoro positional isomers in the pentyl group";

(*t*) by inserting, immediately after item (37) of paragraph 18, the following item:

"(37A) 2-[1-Pent-4-en-1-yl]-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid and its hexanoic acid isomers and their respective pentenyl positional isomers in the pentyl group";

(*u*) by inserting, immediately after item (38) of paragraph 18, the following item:

"(38AAA) 1-Pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide (also known as Cumyl-PICA) and its phenylpropyl isomers"; and

(*v*) by inserting, immediately after item (38AA) of paragraph 18, the following items:

"(38AB) 5-{3-[(2-Phenylpropan-2-yl)carbamoyl]-1H-indol-1-yl}pentanoic acid and its phenylpropyl isomers

(38AC) 2-(2-Phenylpropan-2-yl)-5-pentyl-pyrido[4,3-b] indol-1-one (also known as 2-Cumyl-5-pentylgamma-carbolin-1-one or cumyl-PEGACLONE or SGT-151) and its phenylpropyl isomers

(38AD) 1-Propionyl-N,N-diethyllysergamide (also known as 1-Propionyl-LSD or 1P-LSD) and its acyclic secondary and tertiary amide structural isomers

(38AE) 6-Propyl-6-nor-lysergic acid diethylamide (also known as PRO-LAD) and its acyclic secondary and tertiary amide structural isomers".

Amendment of Part I of Third Schedule

3. Paragraph 1 of Part I of the Third Schedule to the Misuse of Drugs Act is amended by inserting, immediately below the item "Lysergic acid also known as 9,10-Didehydro-6-methylergoline-8β-carboxylic acid", the following item:

"Methyl alpha-phenylacetoacetate (also known as MAPA)".

Amendment of Fifth Schedule

4. Paragraph 1 of the Fifth Schedule to the Misuse of Drugs Act is amended by deleting items (1) to (8) and substituting the following items:

"(1) 4-Bromo-N-[2-(dimethylamino)cyclohexyl]-benzamide (also known as Bromadoline or U-47931E) and its bromo positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring

(2) 4-Bromo-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (also known as N-Methyl U-47931E or N-Methyl Bromadoline) and its bromo positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring

(3) 3,4-Dibromo-N-methyl-N-(1-methyl-1-azaspiro[4.5]decan-6-yl) benzamide (also known as U-77891) and its dibromo positional isomers in the phenyl ring and their respective azaspiro[4.5] decanyl isomers".

Made on 29 April 2020.

PANG KIN KEONG
Permanent Secretary,
Ministry of Home Affairs,
Singapore.

[MHA 112/2/0049; AG/LEGIS/SL/185/2020/6 Vol. 1]